• All
  • Primary Antibodies
  • Conjugated Antibodies for IF
  • Conjugated Antibodies for FC
  • Secondary Antibodies
  • Antibody Labeling KitsNew
  • ELISA Kits
  • IHC Kits
  • Magnetic Cell Separation Kits
  • Cytokines & Growth Factors
  • Neutralizing/activating Antibodies
  • Nanobody-based Reagents
  • Accessory Products and Kits
  • Fusion Proteins
×
×
Host
0
Species Reactivity
0
Species Reactivity
0
Conjugate
0
Conjugate
0
Compatible Species
0
Conjugate
0

Recombinant Mouse IGFBP2 protein (His Tag)

Species

Mouse

Purity

>90 %, SDS-PAGE

Tag

His Tag

Activity

not tested

Cat no : Eg1196

Validation Data Gallery

  • Purity of Recombinant Mouse IGFBP2 was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

    Purity of Recombinant Mouse IGFBP2 was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

Product Information

Purity >90 %, SDS-PAGE
Endotoxin <0.1 EU/μg protein, LAL method
Activity 
Not tested
Expression HEK293-derived Mouse IGFBP2 protein Glu35-Gln305 (Accession# P47877) with a His tag at the C-terminus.
GeneID 16008
Accession P47877
PredictedSize 30.6 kDa
SDS-PAGE 28-33 kDa, reducing (R) conditions
Formulation Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
Reconstitution Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
Storage Conditions
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

IGFBP2 is one of six homologous proteins in the IGFBP family. Based on its ability to bind IGFs with high affinity, IGFBP2 can exert its functions by interacting with IGFs in the circulation to control the function and activity of IGFs, and prevent the interaction between IGFs and IGF receptors.IGFBP2 was found to be highly expressed in many cancers, including glioma, lung cancer, colorectal cancer, ovarian cancer (OC), rhabdomyosarcoma, gastric cancer, breast cancer, bladder cancer, prostate cancer, endometrial cancer, penile squamous cell carcinoma, and hepatocellular carcinoma.

References:

1. Perez-Larraya JG. et al. (2014). Cancer.120(24):3972-3980.
2.Yuan Q.et al. (2019). Biosci Rep. 39(6):387-395.
3. Han S.et al. (2014). PLoS One. 9(4):e93791.
4. Lin Y.et al. (2009). Neuro Oncol. 11(5):468-476
5.Guo C.et al. (2013). PLoS One. 8(9):202-206.